Last updated: February 27, 2026
What is NDC 46122-0329?
NDC 46122-0329 identifies Paliperidone Palmitate (Invega Trinza), a long-acting injectable antipsychotic medication approved by the FDA in 2015 for schizophrenia treatment. It is marketed by Janssen Pharmaceuticals and primarily prescribed for patients requiring extended-release medication.
Current Market Position
Market Size
- Schizophrenia prevalence in the US: 1.5 million adults.
- Long-acting injectable (LAI) antipsychotics penetration: approximately 30% of schizophrenia patients.
- Market share (2022): Invega Trinza holds about 15% of the LAI antipsychotics segment, with competitor dynamics including Risperdal Consta, Abilify Maintena, and Zyprexa Relprevv.
Usage and Prescriptions
- Annual prescription volume (2022): estimated at 250,000 units.
- Units sold (2022): approximately 200,000, reflecting both initial and maintenance doses.
- Reimbursement trends: Favorable, with Medicaid and Medicare accounting for 60% of prescriptions.
Competitive Landscape
- Key competitors: Risperdal Consta, Abilify Maintena, Zyprexa Relprevv.
- Market share distribution (2022): Invega Trinza 15%, Risperdal Consta 35%, Abilify Maintena 25%, Zyprexa Relprevv 10%, others 15%.
Price Analysis
Current Pricing
- Average wholesale price (AWP): approximately $2,800 per 28-day dose.
- Pack pricing: One vial per injection, with a typical treatment plan involving quarterly injections, leading to an approximate annual cost of $33,600 per patient.
Reimbursement and Market Pricing
- Average selling price (ASP): estimated between $2,200 and $2,600 per unit, depending on volume and payer negotiations.
- Patient out-of-pocket (average): $50 to $300 per dose after insurance coverage.
Pricing Trends (2020–2022)
| Year |
Price Range (Per Dose) |
Notes |
| 2020 |
$2,500 – $2,700 |
Stable, slight reduction due to increased competition |
| 2021 |
$2,400 – $2,600 |
Price pressure from biosimilars and generics |
| 2022 |
$2,200 – $2,500 |
Major payers pushing for discounts |
Price Projection (2023–2027)
Factors Influencing Price
- Market penetration: Growth in LAI antipsychotics could increase demand.
- Competition: Entry of biosimilars may pressure prices downward.
- Reimbursement policies: Payers striving for lower costs could tighten formulary access.
- Manufacturing costs: Marginal increases expected, but stable due to established supply chains.
Projected Price Range
| Year |
Expected Price Per Dose |
Assumptions |
| 2023 |
$2,200 – $2,400 |
Stabilization with minor downward pressure |
| 2024 |
$2,150 – $2,350 |
Slight price erosion as biosimilar competition intensifies |
| 2025 |
$2,100 – $2,300 |
Increased biosimilar presence; discounts offered |
| 2026 |
$2,050 – $2,250 |
Market stabilization; pricing asymptotes |
| 2027 |
$2,000 – $2,200 |
Possible further reduction contingent on biosimilar uptake |
Revenue Impact
- Market size: Estimated at 200,000 units annually.
- 2022 revenue estimate: $440–520 million.
- 2027 revenue forecast: $400–440 million, assuming price decline and stable market share.
Risks and Opportunities
Risks
- Market consolidation: Increased biosimilar competition could reduce prices.
- Regulatory changes: Payer pressures for formulary restrictions.
- Patent challenges: Potential patent expirations or litigation affecting exclusivity.
Opportunities
- Market expansion: Growing prevalence of schizophrenia and acceptance of LAI therapies.
- Pricing strategies: Value-based pricing or expanded indications.
- Formulary placements: Securing preferred status could stabilize revenue.
Key Takeaways
- NDC 46122-0329 (Invega Trinza) commands prices around $2,200–$2,600 per dose.
- Market demand remains steady due to schizophrenia prevalence and LAI adoption.
- Strategic pricing adjustments are expected to moderate revenues slightly over the next five years.
- Competition, especially from biosimilars, poses a long-term risk to pricing power.
- Payer negotiations and formulary access will influence pricing outcomes.
FAQs
1. How does Invega Trinza's price compare to other LAI antipsychotics?
It generally costs more than risperidone and aripiprazole LAIs, which range from $1,800 to $2,200 annually, but remains competitive within the segment, given its quarterly dosing schedule.
2. What are the main factors influencing price declines?
Entry of biosimilars, payer negotiations, and increased market penetration of cheaper alternatives exert downward pressure on prices.
3. Will patent expiry affect the pricing?
Potential patent expirations, targeted for 2027–2028, could introduce biosimilars, likely reducing the price and market share.
4. How does reimbursement vary across payers?
Medicaid and Medicare typically negotiate lower prices, while commercial insurers may reimburse closer to ASP, with patient co-pays varying by coverage.
5. What future growth prospects exist for this drug?
Increasing schizophrenia diagnosis rates and greater acceptance of LAIs suggest moderate growth, driven primarily by market expansion rather than price increases.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2015). Invega Trinza (paliperidone palmitate) approval announcement.
[3] CMS. (2022). Medicare Part D Drug Spending.
[4] MarketWatch. (2023). Antipsychotic drugs market analysis.
[5] EvaluatePharma. (2022). Long-acting injectable antipsychotic market projections.
Note: All price figures and market estimates are approximations based on industry reports, published data, and market analysis as of early 2023.
